Does Insurance Status Impact Delivery of Care with Upper Airway Stimulation for OSA?. (February 2020)

• Record Type: Journal Article
• Authors: Patel, Jena; Topf, Michael C.; Huntley, Colin; Boon, Maurits
• Is Part Of: Annals of otology, rhinology & laryngology. Volume 129:Number 2(2020)
• Page Start: 128
• Page End: 134
• Publication Date: 2020-02
• Subjects: upper airway stimulation -- obstructive sleep apnea -- insurance -- drug induced sleep endoscopy -- treatment delay -- prior authorization; Otolaryngology -- Periodicals; 617.51
• DOI: 10.1177/0003489419878454
• Languages: English
• ISSNs: 0003-4894

Abstract

Objective: To understand differences in patient demographics, insurance-related treatment delays, and average waiting times for Medicare and private insurance patients undergoing upper airway stimulation (UAS) for treatment of obstructive sleep apnea (OSA). Methods: Retrospective chart review of all Medicare and private insurance patients undergoing upper airway stimulation (UAS) from 2015 to 2018 at a single academic center. Primary outcomes were insurance-related procedure cancellation rate and time from drug induced sleep endoscopy (DISE) and UAS treatment recommendation to UAS surgery in Medicare versus private insurance patients. Results: In our cohort 207 underwent DISE and were recommended treatment with UAS. Forty-four patients with Medicare and 30 patients with private insurance underwent UAS procedure. Patients with Medicare undergoing UAS were older (67.4 ± 11.1 years) than patients with private insurance (54.9 ± 8.1 years). Medicare patients had a shorter mean wait time of 121.9 ± 75.8 days (range, 15-331 days) from the time of UAS treatment recommendation to UAS surgery when compared to patients with private insurance (201.3 ± 102.2 days; range, 33-477 days). Three patients with Medicare (6.4%) and 8 patients with private insurance (21.1%) were ultimately denied UAS. Conclusion: Medicare patients undergoing UAS have shorter waiting periods, fewer insurance-related treatment delays and may experience fewer procedure cancellations when compared to patients with private insurance. The investigational status of UAS by private insurance companies delays care for patients with OSA. Level of Evidence: 4